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Synopsis   
 
Endothelin-1 promotes cardiomyocyte hypertrophy by inducing changes in gene expression.  
Immediate early genes including activating transcription factor 3 (Atf3), Egr1 and Ptgs2 are 
rapidly and transiently upregulated by endothelin-1 in cardiomyocytes.  Atf3 regulates 
expression of downstream genes and is implicated in negative feedback regulation of other 
immediate early genes.  To identify Atf3-regulated genes, we knocked down Atf3 expression 
in cardiomyocytes exposed to endothelin-1 and used microarrays to interrogate the 
transcriptomic effects.  Of upregulated mRNAs, expression of 23 (including Egr1, Ptgs2) was 
enhanced and expression of 25 was inhibited by Atf3 knockdown.  Using quantitative PCR, 
we determined that knockdown of Atf3 had little effect on upregulation of Egr1 mRNA over 
30 min, but abolished the subsequent decline, causing sustained Egr1 mRNA expression and 
enhanced protein expression.  This resulted from direct binding of Atf3 to the Egr1 promoter.  
Mathematical modelling established that Atf3 can suffice to suppress Egr1 expression.  Given 
the widespread co-regulation of Atf3 with Egr1, we suggest that the Atf3-Egr1 negative 
feedback loop is of general significance.  Loss of Atf3 caused abnormal cardiomyocyte 
growth, presumably resulting from dysregulation of target genes.  Our data therefore identify 
Atf3 as a nexus in cardiomyocyte hypertrophy required to facilitate the full and proper 
growth response.   
 
Short title:  Feedback regulation by Atf3 
 
Keywords: Activating transcription factor 3, immediate early genes, negative feedback, 
cyclooxygenase 2, microarrays, hypertrophy.  
 
Abbreviations used:  Adenovirus, AdV; antisense, AS; chromatin immunoprecipitation, 
ChIP; endothelin-1, ET-1; extracellular signal-regulated kinase, ERK; Gq protein-coupled 
receptor, GqPCR; immediate early gene, IEG; interleukin, IL; mitogen-activated protein 
kinase, MAPK; multiplicity of infection, MOI. 
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INTRODUCTION 
 
Cardiomyocytes, the terminally-differentiated contractile cells of the heart, undergo 
hypertrophy (i.e. increase in cell size) in response to Gq protein-coupled receptor (GqPCR) 
agonists including endothelin-1 (ET-1) [1].  ET-1 particularly activates the extracellular 
signal-regulated kinase 1/2 (ERK1/2) cascade, a pathway that is associated with 
cardiomyocyte hypertrophy [1,2].  ERK1/2 signalling is strongly implicated in transcriptional 
regulation and elicits many longer term effects through changes in gene expression [3].  
Perhaps unsurprisingly therefore, ~70% of the changes in gene expression induced in 
neonatal rat cardiomyocytes over the first 4 h of stimulation with ET-1 requires ERK1/2 
signalling [4-6].   However, activation of ERK1/2 in cardiomyocytes by ET-1 is rapid and 
transient [7], and this phase may be viewed as an initiating trigger of the longer term 
response.  Consistent with this, exposure of cardiomyocytes to ET-1 results in multiphasic 
patterns of gene expression that presumably culminate in hypertrophic growth [5].  Our 
previous studies identified a number of immediate early genes (IEGs; genes that are regulated 
by pre-existing transcription factors) that are particularly rapidly upregulated in 
cardiomyocytes exposed to ET-1 including activating transcription factor 3 (Atf3) [5]. 
 Atf3 is a member of the ATF/CREB family proteins which bind as homo- or 
heterodimers to consensus ATF/CRE sites in gene promoters to regulate transcription [8].   
Like other members, full-length Atf3 possesses a basic region-leucine zipper (bZIP) domain 
for dimerization, although alternative splicing can produce Atf3 isoforms without a bZIP 
domain.  The activity of some ATF/CREB proteins is regulated by phosphorylation, but Atf3 
is largely regulated at the level of expression, being present at very low levels in quiescent 
cells and induced as an IEG by a range of extracellular stimuli (e.g. peptide growth factors, 
GqPCR agonists, cytokines) and cellular stresses (e.g. oxidative stress, 
ischaemia/reperfusion) in a variety of cell types.  Indeed, it is difficult to identify a stimulus 
that does not induce Atf3 expression suggesting that it plays a significant, global role in 
regulating gene expression programmes.  Mitogen-activated protein kinases (MAPKs) 
including ERK1/2 are particularly implicated in promoting Atf3 mRNA expression, 
potentially acting through a variety of transcription factors (e.g. CREB, Atf2, c-Myc) [9-11].  
Several studies also implicate the Egr1 transcription factor in positive regulation of Atf3 
transcription, probably resulting from its phosphorylation and activation by ERK1/2 
[10,12,13]. 
    Atf3 is generally viewed as a transcriptional repressor, particularly when present as 
homodimers.  Thus, Atf3 represses transcription of Gadd153/Chop10 and may also repress 
transcription from its own promoter to limit expression [14].  A systems biology study of 
TLR4 signalling to gene expression in macrophages further confirmed its role as a 
transcriptional repressor, demonstrating that Atf3 is induced by lipopolysaccharide and 
represses expression of interleukin 6 (IL6) and IL12b mRNAs by antagonising NFB-
dependent stimulation of transcription [15].  A similar system operates downstream from 
TLR9 [16], suggesting that negative feedback regulation of cytokine production by Atf3 is a 
feature of the innate immune response [17].  However, Atf3 (potentially as heterodimers with 
other ATF/CREB proteins) promotes transcription of other genes such as proglucagon [18].  
Moreover, in the context of DNA damage in cancer cells, Atf3 may act as a positive regulator 
of gene expression, probably by enhancing p53 function [19].  The dichotomous role of Atf3 
and the variation in underlying mutations that cause cancer presumably account for the 
variation in opinion regarding the role of Atf3 in this disease [17]. 
 As mentioned above, Atf3 is induced in cardiomyocytes by ET-1 as an IEG [5], but it 
is also upregulated in these cells by, for example, doxorubicin [20], oxidative stress [3], 
insulin [21] and hypoxia [22].  Transient ischaemia increases Atf3 expression in whole hearts 
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[22,23], and cardiospecific overexpression of Atf3 in transgenic mice results in pathological 
features of cardiac hypertrophy/failure [24] (this is distinguishable from, though may 
encompass, cardiomyocyte hypertrophy [25]).  Confusingly, cardiac hypertrophy/failure 
induced by pressure-overload is exaggerated in Atf3 null mice [26].  This probably results 
from enhanced signalling through ERK1/2 and other MAPKs, all of which are implicated in 
the development of cardiac pathology [1].  Whilst these studies suggest that control of Atf3 
expression is important in homeostatic control of cardiac function, it is difficult to develop a 
mechanistic understanding of Atf3 function in these models with long-term manipulation of 
Atf3 expression.  We used the cardiomyocyte model to investigate the role of Atf3 in 
negative feedback regulation of IEG expression and positive feedforward regulation of 
second-phase genes.  Adopting an antisense knockdown approach, we identified Egr1 as a 
prime target for Atf3 repression in response to ET-1.  Notably, Egr1 has been associated with 
cardiac hypertrophy for many years [27-29], and our data shed further light on the 
transcriptional networks within which it operates. 
 
 
EXPERIMENTAL 
 
Cardiomyocyte cultures and knockdown of Atf3 with adenoviruses for antisense Atf3   
 
Ventricles from neonatal Sprague-Dawley rat hearts (Harlan UK Ltd) were dissociated by 
serial digestion and cultured as previously described [6].  For immunoblotting, RNA studies 
or ChIP, cardiomyocytes were plated in 15% (v/v) foetal calf serum at a density of 4 × 106 
cells/dish on 60 mm Primaria dishes pre-coated with sterile 1% (w/v) gelatin (Sigma-Aldrich 
UK).  For immunostaining experiments, glass coverslips were placed in Primaria 35 mm 
culture dishes and coated with 1% (v/v) gelatin then laminin (0.2 mg/ml in PBS, 2 h).  
Coverslips were washed with PBS.   Cardiomyocytes were plated at 1.5 ×106 cells/dish in 
serum-containing medium.  After 18 h, cardiomyocytes were incubated in serum-free 
medium for 24 h then unstimulated (controls) or exposed to 100 nM ET-1 (Bachem UK) in 
the presence or absence of cycloheximide (Sigma-Aldrich UK), U0126 or PD184352 (Alexis 
Biochemicals, Enzo Life Sciences).  Agonists/inhibitors were prepared as 1000 stock 
solutions in water (ET-1, cycloheximide) or DMSO (U0126, PD184352) and added directly 
to the tissue culture medium. 
 
 
Preparation of adenoviruses   
 
Replication-deficient AdVs expressing full-length rat Atf3 antisense RNA (AS-Atf3) were 
prepared using the AdEasy™ XL Adenoviral Vector System (Stratagene).  The coding 
sequence for Atf3 was isolated by PCR from rat cardiomyocyte cDNA using Pfu polymerase 
and primers designed to the 5’ start site (5’-ATGATGCTTCAACATCCAGGC-3’) and 3’ 
stop codon (5’-TTAGCTCTGCAATGTTCCTTC-3’) regions, and further amplified with 
primers that included sites for restriction enzymes HindIII (5’-
CTTATCTAGAAGCTTATGATGCTTCAACATCCAGGC-3’) and KpnI (5’-
TAGAGATCTGGTACCTTAGCTCTGCAATGTTCCTTC-3’) for insertion into the multiple 
cloning site of the pShuttle-CMV vector.  Control samples were prepared with empty vector 
(No-AS).  Constructs were sequenced using an ABI 3100 Genetic Analyser.  Shuttle plasmids 
were linearised with PmeI and used to transform BJ5183-AD-1 cells.  AdV plasmids from 
positive recombinants were expanded in XL10Gold cells, linearised with PacI and used to 
transform HEK293 cells.  AdVs were amplified through subsequent re-infection of HEK293 
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cells and titres were determined using Adeno-X Rapid Titer kits (Clontech).  For 
experiments with AdVs, cardiomyocytes were incubated in serum-free medium for 4 h, AdVs 
were added and the cells incubated for a further 48 h.   
 
 
Immunoblotting   
 
Cardiomyocytes were washed in ice-cold PBS and nuclear extracts prepared for 
immunoblotting as described [30].  Proteins (20 µg) were separated by SDS-polyacrylamide 
gel electrophoresis on 10% or 12% polyacrylamide gels and transferred electrophoretically to 
nitrocellulose.  Immunoblotting was performed as described [5].  Primary antibodies to Atf3 
(sc-188), Egr1 (sc-189) and Atf2 (sc-187) were from Santa Cruz Biotechnology Inc. and used 
at 1/1000 dilution.  Secondary antibodies conjugated to horseradish peroxidase were from 
Dako (1/5000 dilution).  Bands were detected using ECL Plus with an ImageQuant 350 
digital imager (GE Healthcare).  ImageQuant 7.0 software was used for densitometric 
analysis. 
 
 
RNA preparation, microarrays and data analysis   
 
Cardiomyocytes were uninfected or infected with empty AdVs or AdVs encoding AS-Atf3 
and then unstimulated (controls) or exposed to 100 nM ET-1 (90 min).  Uninfected 
cardiomyocytes were exposed to ET-1 for 30, 60 or 90 min.  Total RNA was prepared and 
concentrations determined as previously described [5].  To minimise variation resulting from 
different cardiomyocyte preparations, equal amounts of RNA from three individual 
experiments were pooled to generate a single sample set.  Three sets of pooled samples were 
prepared for hybridization to separate Affymetrix rat exon 1.0 ST arrays (i.e. three separate 
sets of samples were analysed for each condition, prepared from a total of 9 myocyte 
preparations).  Samples were prepared for hybridisation using Genechip® WT Sense Target 
Labelling kits (Affymetrix).  For all samples except those from uninfected cells exposed to 
ET-1 for 60 min with their corresponding controls, the rRNA reduction protocol was 
modified and the RiboMinus Transcriptome Isolation Kit (Human/Mouse) (Invitrogen) was 
used according to the manufacturer's instructions with 7 µg of RNA.  Hybridization to 
Affymetrix rat exon 1.0 ST arrays was performed at the CSC/IC Microarray Centre (Imperial 
College London).  For samples from uninfected cells exposed to ET-1 for 60 min with their 
corresponding controls, total RNA was provided to the European Arabidopsis Stock Centre at 
Nottingham (NASC) for preparation and hybridisation to Affymetrix rat Exon 1.0 arrays 
according to their protocols (affymetrix.arabidopsis.info).   Data are available from 
ArrayExpress (accession nos. E-MEXP-3392, E-MEXP-3393, E-MEXP-3394).   
 Data (.CEL files) were imported into GeneSpring 11.5 (Agilent Technologies) using 
the Extended annotations, with RMA16 normalisation and normalisation per gene to 
corresponding uninfected, unstimulated controls within each sample set.  Probesets were 
selected for analysis with baseline expression >50 in all of any of the conditions.  To 
determine effects of AdV infection, probesets were selected with >1.5-fold change in 
unstimulated cells infected with No-AS AdVs relative to uninfected cells, applying an 
unpaired T test with the Benjamini and Hochberg multiple testing correction (FDR<0.05).  
To identify transcripts regulated by Atf3, we selected those which were significantly changed 
(>1.5-fold; FDR<0.05) in uninfected cells in response to ET-1 at 30, 60 or 90 min (unpaired 
T-tests with the Benjamini and Hochberg multiple testing correction).  For transcripts with 
<1.2-fold change in baseline expression with No-AS AdVs, subsequent analysis employed an 
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interpretation with AdV infected conditions, using statistical testing (one-way ANOVA with 
SNK post-test and Benjamini and Hochberg multiple testing correction) and filtering on the 
basis of >1.5-fold difference between AS-Atf3 and No-AS infected cells.  For transcripts with 
>1.2-fold change in baseline expression with No-AS AdVs, subsequent analysis employed an 
interpretation with all conditions, using statistical testing (one-way ANOVA with SNK post-
test and the Benjamini and Hochberg multiple testing correction) to identify mRNAs with 
significant difference between cells infected with AS-Atf3 and No-AS AdVs or uninfected 
cells, but with no significant difference between uninfected cells and those infected with No-
AS AdVs with exposure to ET-1 (90 min) and/or in unstimulated cells.  Further filtering 
identified transcripts with >1.5-fold difference between cells infected with AS-Atf3 and those 
infected with No-AS AdVs or uninfected cells. 
 
 
PCR   
 
Cardiomyocytes were treated and total RNA extracted as for microarray analysis.  cDNAs 
were synthesized using High Capacity cDNA Reverse Transcription Kits with random 
primers (Applied Biosystems).  Semi-quantitative PCR (sqPCR) and quantitative qPCR were 
performed as previously described [5] using primers listed in the Supplemental Information, 
Table 6 online.   Values were normalized to glyceraldehyde 3-phosphate dehydrogenase 
(Gapdh) expression and then to control values. 
 
 
Chromatin immunoprecipitation   
 
Cardiomyocytes (16 × 106 cells per sample) were unstimulated or exposed to 100 nM ET-1 
and fixed in 1% (v/v) formaldehyde (10 min).  The reaction was terminated with 125 mM 
glycine (10 min).  Cells were washed and harvested in ice-cold PBS containing 
protease/phosphatase inhibitors [5], collected by centrifugation (3000 × g, 4°C, 5 min) and 
lysed (15 min, 4°C) in 50 mM Tris-HCl pH 8.0, 2 mM EDTA, 0.1% (v/v) Nonidet P40, 10% 
(v/v) glycerol containing protease/phosphatase inhibitors.  Nuclei were pelleted (3000 × g, 
4°C, 5 min), resuspended in 50 mM Tris-HCl pH 8.0, 1% (w/v) SDS, 5 mM EDTA, and the 
DNA sheared to 200 - 800 bp fragments by sonication (5 × 30 s with 2 min recovery, 4°C).  
Following centrifugation (4000 × g, 4°C, 5 min), the supernatants were retained and a sample 
reserved for input DNA.  The remainder was diluted in 50 mM Tris-HCl pH 8.0, 0.5% (v/v) 
Nonidet P40, 200 mM NaCl, 0.5 mM EDTA.  Samples were pre-cleared with protein A-
Sepharose then incubated without or with 0.01 mg Atf3 antibodies (Santa Cruz 
Biotechnology Inc.; catalogue number, sc-188X) with rotation (4°C, overnight).  Protein A-
Sepharose was added together with sonicated salmon sperm DNA (1 µg/ml) and samples 
were incubated (4°C, 2 h).  Beads were pelleted by centrifugation (1000 × g, 4°C, 3 min) and 
washed (4°C, 3 min) in 20 mM Tris-HCl pH 8.0, 0.1% (w/v) SDS, 1% (v/v) Nonidet P40, 2 
mM EDTA, 500 mM NaCl followed by 10 mM Tris-HCl pH 8.0 containing 1 mM EDTA.  
Immune complexes were eluted (10 min, 65°C) in 10 mM Tris-HCl pH 8.0, 1 mM EDTA, 
1% (w/v) SDS.  Samples were centrifuged (200 × g, 1 min) and supernatants collected.  
Crosslinks were reversed by incubation (65°C, overnight) with 0.2 M NaCl.  Samples were 
incubated (5 min, 4°C) with phenol:chloroform:isoamyl alcohol (25:24:1, pH 8.0) and the 
phases separated by centrifugation (15,300 × g, 4°C, 10 min).  DNA in the upper aqueous 
phase was precipitated with isopropanol (-80°C, 3 h), recovered by centrifugation (15,300 × 
g, 10 min, 4°C), washed (70% (v/v) ethanol) and resuspended in nuclease free water for PCR.  
PCR reactions were performed using specific primers: Egr1, Forward 5’ 
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ACTGCCGCTGTTCCAATACT 3’, Egr1 Reverse 5’ CGAATCGGCCTCTATTTCAA 3’; 
Ptgs2, Forward 5’ GCAGCAAGCACGTCAGACT 3’, Ptgs2 Reverse 5’ 
TAACCCGGAGAACCTTGCTT 3’; IL6, Forward 5’ TGCTCAAGTGCTGAGTCACT 3’, 
IL6 Reverse 5’ AGACTCATGGGAAAATCCCA 3’.  Primers for an arbitrary downstream 
sequence ~2000 bp 3' to the IL6 promoter: Forward 5’ CACCTCTCCACCCTGACATT 3’, 
Reverse 5’ CCAACTAGACAGCCCAGAGC 3’.  PCR amplification conditions were: 34 
cycles denaturing, 95°C, 30 s; annealing, 60°C, 30 s; extension 72°C, 45 s.  PCR products 
were visualized on 2% (w/v) agarose gels with Sybr-Safe (Invitrogen) and the bands captured 
under UV illumination.  Densitometric analysis was performed using Imagemaster 1D Prime, 
version 3.0 (GE Healthcare). 
 
 
Immunostaining   
 
Cardiomyocytes were exposed to 100 nM ET-1, then washed with PBS and fixed in 4% (v/v) 
formaldehyde (10 min, room temperature).  Immunostaining was performed as described 
previously [31] using mouse monoclonal primary antibodies to troponin T (1/40, 60 min; 
Stratech Scientific, catalogue no. MS-295-P1) and Alexa Fluor®488 anti-mouse secondary 
antibodies (1/200, 60 min).  Coverslips were mounted using fluorescent mounting medium 
(Dako) and viewed using a Zeiss Axioskop fluorescence microscope.  Images were captured 
using a digital camera (1600 × 1200 pixels resolution, 1.4× zoom factor, 160 × 120 µm field 
dimension).  Colour images were converted to Greyscale using Adobe Photoshop. 
 
 
Statistical analysis   
 
Statistical analysis of microarray data used GeneSpring 11.5.  Other analyses used GraphPad 
Prism 4.0. 
 
 
RESULTS 
 
Regulation of Atf3 expression in cardiomyocytes by ET-1 and identification of Atf3 
target genes 
 
ET-1 (100 nM) stimulated a rapid, transient increase in expression of Atf3 mRNA in 
cardiomyocytes (Figure 1A).  Expression was maximal within 30 min, declining rapidly 
thereafter.  Cycloheximide (a protein synthesis inhibitor) did not inhibit the response, 
indicating that Atf3 was regulated as an IEG (Figure 1B), and upregulation of Atf3 mRNA by 
ET-1 was inhibited by U0126 or PD184352, inhibitors of the ERK1/2 cascade (Figure 1, B 
and C).  Atf3 protein was also increased by ET-1 (maximal at 1 h) (Figure 1D).  To suppress 
expression of Atf3, we generated adenoviruses (AdVs) encoding full-length Atf3 in the 
antisense orientation (AS-Atf3), using empty AdVs with no AS-Atf3 (No-AS) to control for 
effects of viral infection.  Effective knockdown of Atf3 protein induced by ET-1 was 
obtained using 150 MOI AS-Atf3 AdVs with limited effect of No-AS AdVs and no effect on 
expression of Atf2 (Figure 1, E-G). 
 Uninfected cardiomyocytes or cardiomyocytes infected with 150 MOI No-AS or AS-
Atf3 AdVs were unstimulated or exposed to 100 nM ET-1 for 90 min (since expression of 
Atf3 protein was maximal at 1 h, Figure 1D, we expected to detect downstream consequences 
by 90 min) and mRNA expression profiling was performed (Affymetrix rat exon 1.0 ST 
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microarrays).  As expected, No-AS AdV infection alone significantly (>1.5-fold; FDR<0.05) 
affected expression of a subset of mRNAs (156 mRNAs upregulated; 59 mRNAs 
downregulated), many of which are associated with a viral response and/or 
cytokine/chemokine signalling in other cells (Figure 2; Supplemental Information, Table 1).   
 To determine the effects of Atf3 in the ET-1-responsive myocyte transcriptome, 
probesets were selected with significant changes in expression (>1.5-fold, FDR<0.05) 
induced by ET-1 at 30, 60, or 90 min (334 upregulated and 109 downregulated mRNAs).  
From these, we identified 90 mRNAs that were upregulated by ET-1 and affected by Atf3 
knockdown (Figure 3A; Supplemental Information, Tables 2 - 4 online).  Of upregulated 
transcripts without baseline effect of viral infection (75 mRNAs), AS-Atf3 enhanced the 
response of 15 mRNAs (clusters A1 and A2), inhibited the response of 18 mRNAs (clusters 
B1 and B2) and, for 42 mRNAs (cluster C), AS-Atf3 enhanced the response in unstimulated 
cells without further effect on the response to ET-1.  Of upregulated mRNAs with baseline 
(>1.2-fold change) effect of viral infection, the response to ET-1 was enhanced or inhibited 
by AS-Atf3 for 8 (cluster D) or 7 (cluster E) mRNAs, respectively.  With ET-1 
downregulated mRNAs (Figure 3B; Supplemental Information, Table 5 online), we identified 
only 5 mRNAs for which AS-Atf3 reduced the magnitude of the downregulation by ET-1 
(cluster F) and 5 mRNAs for which AS-Atf3 increased the magnitude of the response (cluster 
G).  Having previously defined IEG vs downstream gene expression for mRNAs upregulated 
by ET-1 (Affymetrix rat genome 230 2.0 arrays) [5], we cross-referenced the datasets 
(Supplemental Information, Tables 2 and 4 online).  A greater proportion of mRNAs in 
clusters A1, A2 and D (Atf3 knockdown enhanced ET-1-induced expression) were IEGs 
rather than second-phase genes, consistent with negative feedback by Atf3.  A greater 
proportion of mRNAs in clusters B1 and B2 (Atf3 knockdown inhibited ET-1-induced 
expression) were second-phase genes rather than IEGs suggesting that Atf3 plays a positive 
feed-forward role in these cases (genes in cluster E were not identified in the previous dataset 
[5]).  Overall, we conclude that upregulation of Atf3 by ET-1 in cardiomyocytes plays a 
significant role in modulating the response of other upregulated genes, and a minor role in 
regulating mRNAs that are downregulated by ET-1.   
 
 
Negative regulation of Egr1 and Ptgs2 expression by Atf3 
 
Microarray data were validated by qPCR, selecting IEGs with enhanced expression of the 
ET-1 response by AS-Atf3 (Egr1, Ptgs2) and non-IEGs with reduced expression by AS-Atf3 
(Areg, Dusp5) for analysis.  For Egr1 and Ptgs2, the relative increase in expression induced 
by ET-1 at 0.5 h was similar in cardiomyocytes expressing No-AS or AS-Atf3 (Figure 4, A 
and B), indicating that Atf3 was not involved in this upregulation phase.  AS-Atf3 produced 
sustained expression of Egr1 mRNA (Figure 4A) and enhanced expression of Ptgs2 at 
subsequent times (Figure 4B), consistent with negative feedback of Atf3 on these two genes.  
In contrast, AS-Atf3 inhibited expression of Areg (Figure 4C) and Dusp5 (Figure 4D).  The 
qPCR data (Figure 4, left panels) are consistent with the microarray results (Figure 4, right 
panels).  Dusp1 (an IEG) and Il1rl1 (a non-IEG) were not significantly affected by AS-Atf3 
in our microarray experiments and there was no difference in the relative changes in 
expression induced by ET-1 in cardiomyocytes expressing No-AS or AS-Atf3 (Figure 4, E 
and F).  Thus, our selection criteria were not excessively stringent.  Finally, although others 
identified IL6 as a target for negative feedback by Atf3 in the context of inflammation [15], 
there was no difference in relative expression of IL6 mRNA in cardiomyocytes expressing 
No-AS or AS-Atf3 following stimulation with ET-1 at any time studied (Figure 4G).  To 
validate the Atf3-Egr1 feedback loop further, we examined the effect of AS-Atf3 on Egr1 
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protein expression following induction with ET-1.  AS-Atf3 (but not No-AS) inhibited 
expression of Atf3 for the 150 min period studied (Figure 5, A and B).  AS-Atf3 did not 
substantially increase the total amount of Egr1 protein at 60 min, but levels remained 
elevated up to ~105 min (Figure 5, A and C).  After this time Egr1 protein declined, but 
levels remained elevated up to at least 150 min.   
 Chromatin immunoprecipitation (ChIP) with antibodies to Atf3 was used to determine 
if Atf3 binds directly to the Egr1 and Ptgs2 promoters.  The Egr1 promoter contains two CRE 
elements [32], and a CRE-element potentially subject to negative regulation by Atf3 has been 
identified in the Ptgs2 promoter [33,34].  We used primers either side of these sequences for 
ChIP-PCR (Figure 6, A and C).  For both genes, the amount of ChIP-PCR product in 
unstimulated cells was similar to that of no-antibody controls and stimulation with ET-1 (1 h) 
substantially increased the amount of ChIP-PCR product (Figure 6, B and D).  Thus, Atf3 
binds directly to Egr1 and Ptgs2 promoters to inhibit transcription.  Interestingly, ChIP-PCR 
for the IL6 promoter (Figure 6E) demonstrated binding of Atf3 (Figure 6F) despite there 
being no effect of Atf3 knockdown on expression of IL6 mRNA (Figure 4G).  This is 
discussed below, but potentially results from ET-1 signalling through ERK1/2 rather than 
NFκB.  The specificity of the ChIP-PCR experiments was demonstrated by PCR across an 
arbitrary sequence approximately 2000 bp downstream of the IL6 promoter (Figure 6G). 
 
 
Mathematical modelling of the Atf3-Egr1 negative feedback loop 
 
Atf3 appears to be a dominant negative regulatory factor in suppressing Egr1 transcription 
(Figure 4A), but we cannot eliminate the possibility of additional negative regulatory 
elements from the experimental data.  We therefore developed a deterministic ordinary 
differential equation model for the Atf3-Egr1 feedback system (Figure 7A) to determine 
whether Atf3 expression can suffice to suppress Egr1 transcription.  We assumed the 
following: Atf3 and Egr1 are co-regulated through ERK1/2 signalling (expression of each 
requires a similar degree of ERK1/2 signalling [5]); ERK1/2 promote expression by 
increasing transactivating activities of transcription factors pre-bound to both promoters (i.e. 
the transcription factor/promoter is viewed as a single entity regulated by ERK1/2 
binding/phosphorylation); it was not necessary to consider ERK1/2 or Atf3 signal termination 
(i.e. no attempt was made to switch off the signal).  The model was informed initially by 
parameters derived in this study and from published literature (Supplemental Information, 
Mathematical Modelling online).   
 We initially assumed that Atf3 suppression of Egr1 mRNA transcription was 
competitive with the positive ERK1/2 signal, but this did not give a good fit to the 
experimental data.  An alternative model in which Atf3 eliminates the ERK1/2 signal 
(modelled by removing the ERK1/2 signal upon Atf3 binding, Figure 7A) gave a good 
qualitative fit.  Adjusting the rate of mRNA synthesis to 275 b/s (within the recently 
estimated range of 55 to >800 b/s [35,36]) for calculation of the rates of transcription of Egr1 
and Atf3 mRNAs, and adjusting parameters for association of phosphorylated ERK1/2 with 
Egr1 and Atf3 DNA (see Supplemental Information, Mathematical Modelling online) gave a 
very good fit to the experimental data in terms of magnitude of variation in Egr1 mRNA 
(~20-fold, Figure 4A), and a relatively good fit (qualitatively) to the suppression of Egr1 
mRNA by Atf3.  The best fit model was obtained with a rate of Atf3 suppression of Egr1 
transcription (k7) in the range 1 × 10
5(Ms)−1 ≤ k7 ≤ 6 × 10
5(Ms)−1 (Figure 7B).  Modelling the 
system in the absence of Atf3 (to mimic Atf3 knockdown) resulted in a similar rate of 
production of Egr1 mRNA to ~0.5 h, with sustained expression thereafter (Figure 7B, centre 
left panel), a profile that replicates the experimental data (Figure 4A, left panel).  Thus, Atf3 
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alone can account for the suppression of Egr1 mRNA expression and probably does so by 
over-riding the positive ERK1/2 signal. 
 
 
Effects of Atf3 on morphological changes induced in cardiomyocytes by ET-1 
 
To determine the consequences of knockdown of Atf3 for ET-1-induced hypertrophy, we 
examined the effects of AS-Atf3 AdVs on myocyte morphology by immunostaining for 
troponin T, a component of the myofibrillar apparatus.  As shown previously [37,38], 
uninfected and unstimulated cardiomyocytes appear small with disorganised myofilaments 
(Figure 8A).  Stimulation with ET-1 increased cell size, increased the content/organisation of 
myofilaments and promoted formation of cell-cell contacts (Figure 8B), classic features of 
hypertrophy.  No-AS AdVs increased myofibrillar content to a small degree in unstimulated 
cells (Figure 8C), but had no overt effect on morphological changes induced by ET-1 (Figure 
8D).  Relative to No-AS AdVs, AS-Atf3 AdVs had no effect on unstimulated cells, but 
resulted in abnormal morphology following ET-1 stimulation with "clumping" of cells and 
generation of elongated processes extending between them (Figure 8, E - H).  It is unclear if 
this is an effect on hypertrophy per se or whether there is a loss of cell-cell or cell-matrix 
adhesion.  Thus, although Atf3 is transiently upregulated within the first hour of stimulation, 
it has a significant effect on long-term phenotypic changes. 
 
 
Discussion 
 
Atf3 is emerging as an extremely important feedback regulator of transcription in general.  
Greatest emphasis has been placed on its role in inflammation and it is clear that Atf3 is 
essential for restraining the immune response [15,17].  However, although viewed as a stress-
regulated and stress-regulatory gene, Atf3 is also upregulated in many cells by growth stimuli 
including peptide growth factors and GqPCR agonists [5,39-41].  The genes that Atf3 
regulates in a growth context are likely to differ from those that it regulates in a stress 
response.  Here, we identify a number of genes that are regulated in cardiomyocytes in 
response to ET-1 for which Atf3 plays either a negative feedback or positive feedforward role 
(Figure 3).  Since loss of Atf3 results in a severely abnormal response to ET-1 (Figure 8), 
strict regulation of any or all of these targets must be important in ensuring an appropriate 
hypertrophic growth response.  However, of all the potential targets, Egr1 emerged as a 
significant candidate and we provide substantial evidence that Atf3 is a transcriptional 
repressor for Egr1 in the ET-1 response.  Thus, Atf3 knockdown leads to sustained 
expression of Egr1 mRNA and enhanced expression of Egr1 protein, and Atf3 binds directly 
to the Egr1 promoter.  Furthermore, mathematical modelling of the system established that 
Atf3 alone can suffice to suppress Egr1 mRNA expression. 
 Egr1 was among the first IEGs to be identified [42] and it is upregulated in many cells 
in response to a wide range of growth stimuli [43].  As such, it is implicated in a host of 
different systems including kidney differentiation [44], macrophage differentiation [45], the 
nervous system and learning/memory [46,47], the immune response [48], wound healing and 
tissue repair [49], prostate cancer [50] and acute lung injury [51].  In the vascular system, 
Egr1 is associated with excessive smooth muscle cell proliferation resulting in in-stent 
restenosis following angioplasty [52].  Egr1 is also implicated in cardiac/cardiomyocyte 
hypertrophy.  Thus, expression of Egr1 is increased in cardiomyocytes and the heart in 
response to a variety of hypertrophic stimuli [27,28], and loss of Egr1 attenuates the 
hypertrophic response [29].  The importance of Egr1 in such a range of systems, together 
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with the emergence of Atf3 as a negative feedback regulator and the co-regulation of the two 
genes in many situations, raises the possibility that the Atf3Egr1 negative feedback loop is 
of broad general significance required to restrict expression of Egr1 and maintain a normal 
growth response. 
 Although Atf3 and Egr1 are co-regulated by a range of stimuli, their upregulation is 
usually rapid and transient.  As transcription factors, IEGs such as Atf3 and Egr1 are 
important in regulating downstream gene expression and dysregulation leads to functional 
abnormalities and abnormal phenotypic responses.  As we demonstrated (Figure 8), 
cardiomyocyte hypertrophy cannot proceed normally in the absence of Atf3.  This is not 
inconsistent with induction of cardiac hypertrophy in mice in vivo by overexpression of Atf3 
[24].  Atf3 knockout also enhances cardiac hypertrophy induced by pressure-overload in mice 
but, in this model, MAPK signalling (including ERK1/2) induced by pressure-overload is 
significantly enhanced [19] and this alone could account for enhanced hypertrophy [2,53].  
Intriguing questions relate to how Atf3 modulates MAPK signalling and if the upregulation 
of MAPK signalling is a compensatory mechanism for loss of Atf3.  Other studies indicate 
that Atf3 is important in regulating, for example, the immune response [15,17], liver function 
[54] and pancreatic -cell function [55,56].  Because of this, it is important to identify the 
genes that Atf3 regulates.    
 At least two previous studies took a systems approach to identify Atf3-regulated 
genes, neither of which identified Egr1 as a target.  The first focused on TLR4 signalling and 
the effects of lipopolysaccharide on the macrophage transcriptome [15].  The strategy used 
Cytoscape (software that draws on published literature to identify protein-protein 
interactions) to predict Atf3-regulated genes from microarray data for subsequent 
experimental verification.  Atf3 was particularly implicated in negative regulation of IL6.  
IL6 is upregulated in cardiomyocytes by ET-1 as we have previously reported [57] and as we 
show in this study (Figure 4G).  We also previously reported preliminary data on the effects 
of AS-Atf3 AdV infection on IL6 mRNA expression.  In those experiments, low viral titres 
and a low MOI (<15) were used to suppress the increase in expression of Atf3 by 10 nM ET-
1 (rather than 100 nM ET-1 used here).  As in this study, AS-Atf3 AdVs enhanced the 
increase in IL6 mRNA induced by ET-1 [57].  Our interpretation was that Atf3 suppressed 
IL6 transcription, consistent with the report on the role of Atf3 in the TLR4 response [15].  
However, we know now that AdV infection has substantial effects on elements of the 
cardiomyocyte transcriptome and on IL6 in particular (Figure 2), and the data in the earlier 
report require re-interpretation.  With submaximal virus and agonist concentrations (rather 
than the saturation levels used in this study), slight differences between No-AS and AS-Atf3 
viral titres were likely to be exaggerated.  The No-AS AdV titre may have been slightly less 
than that of the AS-Atf3 AdVs and this could account for the significant effect of AS-Atf3 on 
IL6 mRNA expression in control cells over and above that induced by the empty virus.  We 
assumed that this indicated a basal effect of Atf3 on IL6 mRNA expression.  However, if the 
effect of AS-Atf3 in control cells is taken into account, ET-1 stimulation of IL6 mRNA was 
similar (~4-fold) in cardiomyocytes infected with either No-AS or AS-Atf3 AdVs.  We now 
therefore consider that Atf3 knockdown did not influence the increase in expression of IL6 
mRNA induced by ET-1.  The lack of an effect of Atf3 knockdown on the increase in IL6 
mRNA expression induced by ET-1 in contrast to the TLR4 response probably reflects a 
fundamental difference in the signalling mechanisms.  TLR4 signals predominantly through 
NFB and suppression of IL6 expression by Atf3 results from its interaction with and 
inhibition of NFB [15].  ET-1 signals predominantly through ERK1/2 to upregulate 
expression of IL6 [5].  With little/no signal through NFB, Atf3 is unlikely to inhibit 
transcription of IL6.  However, Atf3 still binds to the IL6 promoter (Figure 6G).  It is less 
clear why Egr1 was not identified as an Atf3-regulated gene in the TLR4 study [15].  One 
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reason may be that Cytoscape is informed only by published data.  Hence, the study focused 
on the Atf3/NFB interaction and all validations centred on the NFB response.   
 The second study identifying Atf3-regulated genes focused on DNA damage in cancer 
cells.  Here, 5,984 potential Atf3-binding promoters were identified in HCT116 colon cancer 
cells subjected to DNA damage and 1,493 were identified in LNCaP prostate cancer cells 
exhibiting enhanced Atf3 expression [19].  In contrast to TLR4 signalling in macrophages 
[15], Atf3 plays a greater role in positive regulation of mRNA expression in these cancer 
cells, and there was no obvious effect of Atf3 knockdown on Egr1 expression.  However, this 
paradigm differs radically from a growth response associated with IEG expression: Atf3 
upregulation is delayed (mRNA and protein expression are maximal at 6 and 12 h, 
respectively) and potentially driven by p53 [58] with many of the Atf3-regulated genes being 
classic p53 targets [19].  It should also be considered that cancer cell lines were used rather 
than primary cells, and this may influence the signalling/gene expression response. 
 Since Atf3 and Egr1 are co-regulated in many systems, it is worth considering the 
extent to which the Atf3-Egr1 feedback mechanism operates.  We expect it will apply in 
cardiomyocytes exposed to other stimuli that regulate gene expression primarily through 
MAPK signalling.  We suggest that the Atf3-Egr1 negative feedback loop operates in other 
systems that also drive gene expression primarily through ERK1/2 signalling, but this awaits 
further investigation. 
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Figure legends 
 
Figure 1  Atf3 mRNA and protein is increased in cardiomyocytes exposed to ET-1 and 
suppressed by AS-Atf3   
 
A - C, Cardiomyocytes were unstimulated (control) or exposed to 100 nM ET-1 for the times 
indicated (A) or were exposed for 0.5 h to 20 µM cycloheximide (CHX), 10 µM U0126, ET-
1, or ET-1 in the presence of CHX or U0126 (B) or were exposed to ET-1 in the absence or 
presence of 2 µM PD184352 (C).  RNA was extracted and Atf3 mRNA expression measured 
by sqPCR (A and B) or qPCR (A and C).  For A and B, representative sqPCR images are for 
Atf3 (upper image, 388 bp amplicon) and Gapdh (lower image, 412 bp amplicon).  Positions 
of markers are shown on the left and controls with no reverse transcriptase (RT) were 
negative.  Densitometric analysis for sqPCR of Atf3 is shown in the lower panels.  In A, 
sqPCR and qPCR data are compared and results are a range from 0 (control values) to 1 
(maximal expression at 0.5 h).  All data were normalised to Gapdh and are means ± SEM for 
3 or 4 myocyte preparations.  D, Cardiomyocytes were exposed to ET-1 for the times 
indicated and nuclear extracts (20 µg protein) immunoblotted with antibodies to Atf3 using 
12% polyacrylamide gels.  Atf3 was detected as a band of ~ 21 kDa.  A representative image 
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is shown (upper panel) with densitometric analysis (lower panel).  Results are means ± SEM 
for 3 myocyte preparations.  E - G, Cardiomyocytes were infected with No-AS or AS-Atf3 
AdVs at the indicated MOI and unstimulated (control) or stimulated with 0, 10 or 100 nM 
ET-1.  Nuclear extracts were immunoblotted for Atf3 using 12% (E and F) or 10% (G) 
polyacrylamide gels.  In G, the blots were divided into upper and lower sections and were 
probed with antibodies to Atf2 and Atf3, respectively.  Atf2 was detected at ~70 kDa.  @ 
p<0.05 relative to ET-1, * p<0.001 relative to control, ** p<0.01 relative to control, # 
p<0.001 relative to ET-1, (one way ANOVA with SNK post-test).   
 
 
Figure 2 Infection with AdVs modulates expression of a subset of cardiomyocyte 
mRNAs 
 
Cells (uninfected or infected with 150 MOI FLAG or AS-Atf3) were unstimulated or exposed 
to ET-1 for 90 min and RNA expression profiles determined using Affymetrix rat exon 1.0 
ST arrays. A, Heatmaps show expression profiles for probesets that were significantly 
changed (>1.5-fold, FDR<0.05) by viral infection alone. Normalisation is to the gene median 
(range is -2.5 (cyan) through 0 (black) to +2.5 (red) on a log2 scale). Results are means for 3 
hybridisations each representing 3 independent myocyte preparations. Clustering on 
conditions and entities used a Euclidean distance matrix and centroid linkage ratio. B, 
Transcripts were classified according to function. Upregulated and downregulated transcripts 
are in red and blue, respectively. Transcripts regulated by interferons (Ifn) in other systems 
are in lighter colours. 
 
 
Figure 3  Atf3 knockdown modulates the response of the cardiomyocyte transcriptome 
to ET-1 
 
Cardiomyocytes were uninfected or infected with No-AS or AS-Atf3 AdVs (150 MOI), then 
were unstimulated (control) or exposed to ET-1 (100 nM, 90 min).  RNA was extracted and 
analysed using Affymetrix rat exon 1.0 ST arrays.  Analysis of transcripts that were 
upregulated (A) or downregulated (B) by ET-1 identified mRNAs that were significantly 
changed (>1.5-fold; FDR<0.05) by AS-Atf3 compared with No-AS or uninfected cells in the 
absence (clusters, A, B, C and F) or presence (clusters D, E and G) of a statistically 
significant baseline effect(>1.2-fold) of viral infection as determined by GeneSpring analysis 
(p<0.05).  mRNAs were clustered as indicated.  Heatmaps are shown for each cluster with 
normalisation uninfected controls (range: -2.5 (cyan) through 0 (black) to +2.5 (red) on a log2 
scale).  Results are means for 3 hybridisations each representing 3 independent myocyte 
preparations.  Clustering on entities used a Euclidean distance matrix and centroid linkage 
ratio.  Histograms are means ± SEM for the relative mRNA expression for each cluster.  Each 
cluster was subjected to further statistical analysis independently of the global GeneSpring 
analysis.  * p<0.001 relative to No-AS ET-1, ** p<0.05 relative to No-AS ET-1, # p<0.001 
relative to No-AS control, ## p<0.05 relative to No-AS control, @ p<0.05 relative to no virus 
control (one-way ANOVA with SNK post-test).  (N.B. Although the No-AS effect in control 
cells is significant in the context of global statistical testing of microarray data, with the small 
numbers of genes in clusters D and E (with the variation in expression levels) this was not 
significant with secondary testing.  Similarly, for cluster D, although the AS-Atf3 control 
data are significantly different from the no virus control, they are not statistically significantly 
different from the No-AS control). 
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Figure 4  qPCR validation of microarray data  
 
Data were validated for Egr1 (A), Ptgs2 (B), Areg(C), Dusp5 (D), Dusp1 (E), Il1rl1 (F) and 
IL6 (G).  Left panels, Cardiomyocytes were infected with No-AS (open circles, dashed line) 
or AS-Atf3 (closed circles, solid line) AdVs, then exposed to 100 nM ET-1 for the times 
indicated.  RNA was extracted and expression of mRNAs analysed by qPCR.  Results are 
means ± SEM for 3 myocyte preparations. * p<0.05 for AS-Atf3 relative to No-AS at the 
same time point (one-way ANOVA with SNK post-test).  Right panels, Microarray data for 
each of the mRNAs studied are presented relative to uninfected (NV) controls.  Results are 
shown for unstimulated cells (open bars) and cardiomyocytes exposed to ET-1 for 90 min 
(solid bars).  Results are means for 3 independent myocyte preparations and hybridisations. 
 
 
Figure 5  AS-Atf3 expression enhances expression of Egr1 protein in cardiomyocytes 
exposed to ET-1   
 
Cardiomyocytes were uninfected or were infected with No-AS (open circles, dashed line) or 
AS-Atf3 (closed circles, solid line) AdVs, then exposed to 100 nM ET-1 for the times 
indicated.  A, Nuclear extracts (20 µg protein) were immunoblotted for Egr1 (upper images) 
or Atf3 (lower images).  Representative blots of the same nuclear extracts are shown.  B, 
Densitometric data for expression of Atf3 protein.  C, Densitometric data for expression of 
Egr1 protein.  Results were normalised to the no virus samples on each blot and are means ± 
SEM for 3 myocyte preparations.  *, p<0.05 for AS-Atf3 relative to No-AS at the same time 
point (one-way ANOVA with SNK post-test). 
 
 
Figure 6  Chromatin immunoprecipitation (ChIP) assays for binding of Atf3 to Egr1, 
Ptgs2 and IL6 promoters   
 
Cardiomyocytes were unstimulated (control) or exposed to ET-1 (100 nM, 1 h).  Promoter 
sequences with positions of PCR primers and potential Atf3 binding sites are provided in 
panels A (for Egr1), C (for Ptgs2) and E (for IL6) (coding sequence in bold text, underlined; 
5' untranslated region in italics, underlined; positions of primers for PCR in bold, italics; 
potential ATF/CRE binding sites shaded and boxed).  ChIP was performed using antibodies 
to Atf3 with sqPCR across Egr1 (B), Ptgs2 (D) and IL6 (F) promoters.  Representative 
images for input DNA and ChIP DNA are provided (left panels) with densitometric analysis 
(right panels).  Results are means ± SEM for 3 myocyte preparations.  * p<0.05 relative to 
control (Student's t test).  G, ChIP-PCR was performed for an unrelated sequence 
approximately 2000 bp downstream of the IL6 gene.  The experiment was repeated with 
similar results. 
 
 
Figure 7  Mathematical modelling of the Atf3-Egr1 feedback system in the 
cardiomyocyte response to ET-1   
 
A, Schematic diagram of the system.  ET-1 stimulates phosphorylation of MKK1/2 
(MKK1/2-P) which phosphorylates and activates ERK1/2 (ERKERK-P).  ERK-P binds to 
transcription factors (not shown) on the promoters of Egr1 and Atf3 (Egr1 DNA, Atf3 DNA) 
to promote transcription and production of Egr1 mRNA and Atf3 mRNA.  Atf3 mRNA is 
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translated into Atf3 protein that eliminates the positive signal from ERK-P on the Egr1 
promoter.   denotes degradation.  B, Results from the mathematical model derived for the 
schematic in A (see Supplemental Information, Mathematical modelling online) to show the 
rates of accumulation of MKK1/2-P (upper left panel), ERK-P (upper right panel), Egr1 
mRNA (centre left panel), Atf3 mRNA (centre right panel), Atf3 protein (lower left panel) 
and the Atf3 protein/Egr1 DNA complex (lower right panel).  The modelling was performed 
with (red, dashed line) or without (blue, solid line) feedback regulation of Atf3 on the Egr1 
promoter.  (N.B. No attempt was made to switch off either the initial signal from ERK1/2 or 
production of Atf3 mRNA). 
 
 
Figure 8  Atf3 is required for cardiomyocyte hypertrophy induced by ET-1   
 
Cardiomyocytes were uninfected (A and B) or were infected with No-AS (C and D) or AS-
Atf3 (E-H) AdVs, then unstimulated (Control; A, C, E and G) or exposed to 100 nM ET-1 for 
24 h (B, D, F and H).  Cells were immunostained with antibodies to troponin T.  Results are 
representative of 3 independent experiments.  Bar = 50 µm. 
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